Hsp90 inhibitor HSP990 in very low dose upregulates EAAT2 and exerts potent antiepileptic activity

Rationale: Dysfunction or reduced levels of EAAT2 have been documented in epilepsy. We previously demonstrated the antiepileptic effects of Hsp90 inhibitor 17AAG in temporal lobe epilepsy by preventing EAAT2 degradation. Because of the potential toxicities of 17AAG, this study aimed to identify an alternative Hsp90 inhibitor with better performance on Hsp90 inhibition, improved blood-brain barrier penetration and minimal toxicity. Methods: We used cell-based screening and animal models of epilepsy, including mouse models of epilepsy and Alzheimer's disease, and a cynomolgus monkey model of epilepsy, to evaluate the antiepileptic effects of new Hsp90 inhibitors. Results: In both primary cultured astrocytes and normal mice, HSP990 enhanced EAAT2 levels at a lower dose than other Hsp90 inhibitors. In epileptic mice, administration of 0.1 mg/kg HSP990 led to upregulation of EAAT2 and inhibition of spontaneous seizures. Additionally, HSP990 inhibited seizures and improved cognitive functions in the APPswe/PS1dE9 transgenic model of Alzheimer's disease. In a cynomolgus monkey model of temporal lobe epilepsy, oral administration of low-dose HSP990 completely suppressed epileptiform discharges for up to 12 months, with no sign of hepatic and renal toxicity. Conclusions: These results support further preclinical studies of HSP990 treatment for temporal lobe epilepsy.

[1]  Hairong Zheng,et al.  Non-invasive ultrasonic neuromodulation of neuronal excitability for treatment of epilepsy , 2020, Theranostics.

[2]  M. Aschner,et al.  The role of astrocytic glutamate transporters GLT-1 and GLAST in neurological disorders: Potential targets for neurotherapeutics , 2019, Neuropharmacology.

[3]  Weiliang Zhu,et al.  Inhibition of HSP90β Improves Lipid Disorders by Promoting Mature SREBPs Degradation via the Ubiquitin-proteasome System , 2019, Theranostics.

[4]  Fei Gao,et al.  In situ detection of neurotransmitters and epileptiform electrophysiology activity in awake mice brains using a nanocomposites modified microelectrode array , 2019, Sensors and Actuators B: Chemical.

[5]  Yan Shen,et al.  A cynomolgus monkey model of temporal lobe epilepsy , 2019, Brain Research Bulletin.

[6]  A. Marino Gammazza,et al.  Heat Shock Proteins in Alzheimer’s Disease: Role and Targeting , 2018, International journal of molecular sciences.

[7]  I. Ferrer,et al.  Glutamate Transporter GLT1 Expression in Alzheimer Disease and Dementia With Lewy Bodies , 2018, Front. Aging Neurosci..

[8]  R. Panizzutti,et al.  Potential and Challenges for the Clinical Use of d-Serine As a Cognitive Enhancer , 2018, Front. Psychiatry.

[9]  M. Fujimiya,et al.  Activated forms of astrocytes with higher GLT-1 expression are associated with cognitive normal subjects with Alzheimer pathology in human brain , 2018, Scientific Reports.

[10]  Ziming Lu,et al.  Establishment of a rhesus monkey model of chronic temporal lobe epilepsy using repetitive unilateral intra-amygdala kainic acid injections , 2017, Brain Research Bulletin.

[11]  Alice D. Lam,et al.  Silent Hippocampal Seizures and Spikes Identified by Foramen Ovale Electrodes in Alzheimer’s Disease , 2017, Nature Medicine.

[12]  Qibing Mei,et al.  Heat Shock Proteins and Cancer. , 2017, Trends in pharmacological sciences.

[13]  Yan Shen,et al.  Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy , 2017, The Journal of experimental medicine.

[14]  Heidi E Kirsch,et al.  Incidence and impact of subclinical epileptiform activity in Alzheimer's disease , 2016, Annals of neurology.

[15]  O. Decaux,et al.  Hsp90 directly interacts, in vitro, with amyloid structures and modulates their assembly and disassembly. , 2016, Biochimica et biophysica acta.

[16]  A. Planas,et al.  A CNS-permeable Hsp90 inhibitor rescues synaptic dysfunction and memory loss in APP-overexpressing Alzheimer’s mouse model via an HSF1-mediated mechanism , 2016, Molecular Psychiatry.

[17]  Shery Jacob,et al.  A simple practice guide for dose conversion between animals and human , 2016, Journal of basic and clinical pharmacy.

[18]  E. Bonanni,et al.  Effects of antiepileptic drugs on interictal epileptiform discharges in focal epilepsies: an update on current evidence , 2015, Expert review of neurotherapeutics.

[19]  M. Glicksman,et al.  Restored glial glutamate transporter EAAT2 function as a potential therapeutic approach for Alzheimer’s disease , 2015, The Journal of experimental medicine.

[20]  Philippe Bédard,et al.  A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies , 2015, British Journal of Cancer.

[21]  J. Hallak,et al.  Hippocampal expression of heat shock proteins in mesial temporal lobe epilepsy with psychiatric comorbidities and their relation to seizure outcome , 2014, Epilepsia.

[22]  E. Mandelkow,et al.  Hsp90-Tau Complex Reveals Molecular Basis for Specificity in Chaperone Action , 2014, Cell.

[23]  S. Hayashi,et al.  Retinal toxicity induced by small-molecule Hsp90 inhibitors in beagle dogs. , 2014, The Journal of toxicological sciences.

[24]  P. Garriga,et al.  Hsp90 inhibition protects against inherited retinal degeneration , 2013, Human molecular genetics.

[25]  Wei Hu,et al.  A Macaque Model of Mesial Temporal Lobe Epilepsy Induced by Unilateral Intrahippocampal Injection of Kainic Acid , 2013, PloS one.

[26]  G. Holmes,et al.  Hippocampal interictal epileptiform activity disrupts cognition in humans , 2013, Neurology.

[27]  D. Janigro,et al.  Blood–brain barrier dysfunction and epilepsy: Pathophysiologic role and therapeutic approaches , 2012, Epilepsia.

[28]  M. Glicksman,et al.  Glutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases. , 2012, Future medicinal chemistry.

[29]  Qi Xu,et al.  Mapping the Spatio-Temporal Pattern of the Mammalian Target of Rapamycin (mTOR) Activation in Temporal Lobe Epilepsy , 2012, PloS one.

[30]  W. Sellers,et al.  The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo , 2012, Molecular Cancer Therapeutics.

[31]  G. Bates,et al.  Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. , 2011, The Journal of clinical investigation.

[32]  Tian-Le Xu,et al.  Glycine and glycine receptor signaling in hippocampal neurons: Diversity, function and regulation , 2010, Progress in Neurobiology.

[33]  Ryuichi Morishita,et al.  Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in an Alzheimer mouse model with diabetes , 2010, Proceedings of the National Academy of Sciences.

[34]  J. Wolchok,et al.  Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma , 2008, Clinical Cancer Research.

[35]  D. Holtzman,et al.  Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex , 2007, Neurobiology of Disease.

[36]  A. Nehlig,et al.  Neuronal–glial interactions in rats fed a ketogenic diet , 2006, Neurochemistry International.

[37]  E. Zuhowski,et al.  Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1 , 2001, Cancer Chemotherapy and Pharmacology.

[38]  A. Hamberger,et al.  Excitotoxicity , 1994, Molecular Neurobiology.

[39]  Yan Shen,et al.  Deletion of mTOR in Reactive Astrocytes Suppresses Chronic Seizures in a Mouse Model of Temporal Lobe Epilepsy , 2015, Molecular Neurobiology.

[40]  A. Schousboe,et al.  Glutamate and ATP at the Interface of Metabolism and Signaling in the Brain , 2014, Advances in Neurobiology.

[41]  A. Schousboe,et al.  Glutamate metabolism in the brain focusing on astrocytes. , 2014, Advances in neurobiology.